on behalf of the Beta-Blockers in Heart Failure Collaborative Group ABSTRACT BACKGROUND Moderate and moderately severe renal impairment are common in patients with heart failure and reduced ejection fraction, but whether beta-blockers are effective is unclear, leading to underuse of life-saving therapy.
H eart failure (HF) is associated with numerous comorbidities, of which renal dysfunction is both common and of particular importance due to its impact on mortality as well as on the use of guideline-recommended therapies (1) . Patients with HF have a higher incidence of renal dysfunction due to shared pathophysiological pathways and mutual risk factors. In the Swedish HF registry (2) , 51% of 47,716 patients with unselected HF had an estimated glomerular filtration (eGFR) of <60 ml/ min/1.73 m 2 , and in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) program, between 33% and 43% of patients had eGFR <60 ml/min/1.73 m 2 depending on HF phenotype (3) . Impaired renal function is independently associated with worse outcomes; in metaanalyses of 57 studies including trials and cohorts in HF, there was a 2-fold increase in the odds of death comparing patients with and without renal dysfunction (4) .
Renal impairment in HF patients also affects the prescription, dosage, maintenance, and possibly effectiveness of therapies (5, 6) . Although common in clinical practice, patients with renal dysfunction have often been excluded from major clinical trials, creating an evidence gap for many HF patients and a discrepancy with clinical need. Those with moderate renal dysfunction (eGFR 45 to 59 ml/min/1.73 m 2 ) and moderately severe renal dysfunction (eGFR 30 to 44 ml/min/1.73 m 2 ) have a higher risk of adverse outcomes and potentially more absolute benefit from HF therapy, but in addition have multiple comorbidities that can have an impact on clinical management. Previous analyses of beta-blockers in patients with HF and renal dysfunction suggest that efficacy may be maintained at different levels of baseline eGFR (7) (8) (9) (10) . However, the number of patients and events in these studies were limited, particularly at the more severe end of renal impairment, and hence clinicians remain uniformed about any possible interaction of treatment effect. We examined the effect of renal dysfunction on outcomes in patients with HF and reduced ejection fraction (HFrEF) using the totality of individual patient data (IPD) from the landmark, double-blind, randomized controlled trials (RCTs) comparing betablockers with placebo (11) . The Beta-Blockers in Heart Failure Collaborative Group is a multinational project that has systematically harmonized clinical trial data to improve management and outcomes in patients with HF (12) (13) (14) (15) . In this study, we tested the hypothesis that compared with placebo, betablockers reduce mortality in patients with moderate and moderately severe renal dysfunction. Further, we looked at the prognostic impact of renal dysfunction and associated variables, and how change in renal function affects mortality. (29) .
METHODS

DATA COLLECTION AND IPD INTEGRITY.
A standardized data request form to obtain IPD from each trial has been published, along with search results and individual study demographics (11) . IPD were obtained for all 11 trials identified in the systematic review, and data were extracted from original source [18] [19] [20] 24, 25, 27, 28) . There were no patients with missing vital status. Group comparisons were made using the Kruskal Wallis nonparametric rank test. Fractional polynomials were used to find the best transformation of eGFR in adjusted analysis, including nonlinear relationships (for sinus rhythm, the best fit was the inverse square root, and for AF the inverse squared eGFR).
All analyses of beta-blockers versus placebo followed the principle of intention to treat. Outcomes were analyzed using a Cox proportional hazards regression model stratified by study and grouped by heart rhythm and eGFR category. This is a 1-stage fixed-effects approach and assumes that all trials are estimating a common treatment effect with baseline hazards that vary across studies. Hazard ratios (HRs) and 95% confidence intervals (CIs) are presented, along with corresponding p values. We pre-specified adjustment in Cox models for baseline age, sex, LVEF, history of myocardial infarction, systolic blood pressure, heart rate, use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and diuretic therapy. Only a minority of patients were followed for an extended period, and therefore data were censored at 1,200 days (3.3 years) from randomization.
Effect modification was assessed using p values from interaction terms fitted in the multivariable models. The interactions of continuous eGFR with mortality or beta-blocker efficacy were assessed using cubic splines in the Cox model and the Royston- Parmar flexible parametric survival model (30) .
There was no evidence of violation of the proportional hazards assumption in any multivariable model as determined by Schoenfeld residuals. Kaplan-Meier plots were used to graph the pooled, unadjusted data 3) exclusion of CAPRICORN (the only post-infarct trial) and BEST (utilizing a pharmacologically distinct beta-blocker). We also performed sensitivity analyses using all available eGFR measurements for interaction analyses, rather than just the central 99%.
Heterogeneity for pooled outcomes was assessed using the I 2 statistic from a fixed-effects 2-stage model.
We performed post hoc analyses: 1) according to dose achieved at interim follow-up; 2) to assess the relationship between proteinuria and worsening renal function; and 3) using the CKD-EPI (Chronic Kidney Table 4 ). In 2,879 patients with AF at baseline, there was no significant reduction in mortality with beta-blockers in any category of eGFR, and no interaction of beta-blocker efficacy with continuous eGFR (p for interaction ¼ 0.18) ( corresponding mortality increase was 46% for the subset of patients with combined moderate or moderately severe renal impairment at baseline (95% CI: 14% to 87%; p ¼ 0.002; n ¼ 2,175) ( Figure 3) .
In patients with sinus rhythm and moderate or moderately severe renal impairment, 77% managed to reach one-half of the target dose of beta-blocker or greater (compared with 80% with eGFR 60 to 89 ml/ min/1.73 m 2 and 84% with eGFR $90 ml/min/1.73 m 2 ) (Online Table 6 ). These patients had substantially better prognosis than those at lower dose levels (Online Figure 3) ; however, the same pattern was also seen in patients randomized to placebo. Across both sinus rhythm and AF, discontinuation of betablockers was similar to that seen with placebo in patients with moderate and moderately severe renal dysfunction. This was the case for all adverse events leading to therapy discontinuation, and also those specifically related to renal impairment (Online Table 7 ). Overall, discontinuation rates for both beta-blockers and placebo were higher in those with more advanced renal dysfunction. Despite higher rates of comorbidities, the absolute benefit in this group was similar to patients with eGFR >90 ml/min/1.73 m 2 . Discontinuation due to adverse events was the same for both beta-blockers and placebo in these double-blind trials and renal function did not appear to worsen even in those with kidney dysfunction at baseline. These results suggest that renal impairment should not obstruct the prescription of beta-blockers in patients with HFrEF. showed that the benefit of valsartan and spironolactone were consistent in patients above and below an eGFR of 60 ml/min/1.73 m 2 (33, 34) . In more recent trials, no interactions have been noted for renal impairment using this same eGFR cutoff for eplerenone (n ¼ 912) or sacubitril-valsartan (n ¼ 3,061) (35, 36) . However, because the median eGFR in clinical practice is often around 60 ml/ min/1.73 m 2 , it could be argued that a more realistic cutpoint is required to reassure clinicians about the safety and efficacy of therapy. Unfortunately, data specifically in patients with moderately severe renal dysfunction are limited (37) . Subgroup analysis from the MERIT-HF trial (8) , as well as the CIBIS-II (10) and SENIORS (9) trials, suggested potential benefit from beta-blockers in those with eGFR <45 ml/min/1.73 m 2 , hence the need for this analysis that included all of these RCTs and more. HFrEF patients with severe renal dysfunction or kidney failure have largely been excluded from RCTs. One exception was a small trial in 114 dialysis patients, where carvedilol was found to improve clinical status (38 
